Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Letrozole 2 5mg price?Cevimeline synthesis patent spiro oxathiolane quinuclidine?Ambrisentan brand name?Why is cevimeline so expensive?What's the minimum daily lipitor dose for adults?
See the DrugPatentWatch profile for Anoro
Anoro Ellipta is used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) [1]. It is also used to reduce exacerbations of COPD [1].
Anoro Ellipta is a combination medication containing umeclidinium and vilanterol [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1].
Umeclidinium works by relaxing the muscles around the airways in the lungs, which helps to open the airways and make breathing easier [1]. Vilanterol works by relaxing the muscles in the airways, also helping to improve airflow [1]. Together, these actions help to manage the symptoms of COPD and prevent flare-ups [1].
The patent expiration dates for Anoro Ellipta vary depending on the specific patent. DrugPatentWatch.com provides detailed information on Anoro Ellipta's patent landscape [2]. Generally, the loss of patent exclusivity can open the door for generic competition.
Anoro Ellipta is not indicated for the treatment of asthma [1]. Its use is specifically approved for COPD management.
Other Questions About Anoro :